Repository logo
 

Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T1 and T2 Mapping in a PET/MR Setting.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Kaggie, Joshua D 
Kessler, Dimitri A 
McLean, Mary A 
Buonincontri, Guido 

Abstract

Multiparametric magnetic resonance imaging (MRI) can be used to characterize many cancer subtypes including ovarian cancer. Quantitative mapping of MRI relaxation values, such as T 1 and T 2 mapping, is promising for improving tumor assessment beyond conventional qualitative T 1- and T 2-weighted images. However, quantitative MRI relaxation mapping methods often involve long scan times due to sequentially measuring many parameters. Magnetic resonance fingerprinting (MRF) is a new method that enables fast quantitative MRI by exploiting the transient signals caused by the variation of pseudorandom sequence parameters. These transient signals are then matched to a simulated dictionary of T 1 and T 2 values to create quantitative maps. The ability of MRF to simultaneously measure multiple parameters, could represent a new approach to characterizing cancer and assessing treatment response. This feasibility study investigates MRF for simultaneous T 1, T 2, and relative proton density (rPD) mapping using ovarian cancer as a model system.

Description

Keywords

Cancer applications, clinical imaging, imaging techniques, magnetic resonance imaging (MRI), oncology, ovarian cancer

Journal Title

IEEE Trans Radiat Plasma Med Sci

Conference Name

Journal ISSN

2469-7311
2469-7311

Volume Title

3

Publisher

Institute of Electrical and Electronics Engineers (IEEE)
Sponsorship
Cancer Research Uk (None)
Cancer Research UK (CB4150)
The authors acknowledge research support from the National Institute of Health Research Cambridge Biomedical Research Centre, GlaxoSmithKline.Cancer Research UK (CRUK), the CRUK Cambridge Centre, Medical Research Council, CRUK/Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, Addenbrooke's Charitable Trust, and the Cambridge Experimental Cancer Medicine Centre.